QIANGBING YANG MSC

PhD Candidate

Lipid nanoparticle | CRISPR/Cas system | modified mRNA

My research focuses on the treatment of cardiac disease by using lipid nanoparticles to deliver modified messenger RNA encoding various CRSIPR/Cas gene editing systems. There are more than 75,000 known diseases associated with genetic variants in humans remain difficult to correct. The emergence of various CRSIPR/Cas genome editing technologies holds out the promise of a cure for such diseases. We have advanced in vitro synthesis technology of modified mRNA and mature preparation technology of lipid nanoparticle carrier. We integrated the CRISPR/Cas gene editing system with the modified mRNA to give full play to their advantages and provide a more effective, accurate and safe method for the treatment of genetic defects.

Publications:

Yang, Q., et al., Metformin ameliorates the progression of atherosclerosis via suppressing macrophage infiltration and inflammatory responses in rabbits. Life Sciences, 2018. 198: p. 56-64. https://doi.org/10.1016/j.lfs.2018.02.017

E-mail

Q.Yang@umcutrecht.nl

 

©2019 by experimentalcardiologylab. Proudly created with Wix.com. All rights reserved